Weekly Psychedelic Policy Briefing: August 23, 2026

Oregon's psilocybin program posted its first real-world outcome data this week, just as regulators move on fee increases that operators say could close the market. Plus Trump's FDA nominee and Johnson & Johnson's bet on neuroplastogens.